restorative processes and thereby lead to improvement in neurological function. We will describe preclinical work and review the applications of these cell-based and pharmacological restorative approaches to the stroke patient. and carbamylated erythropoietin for the treatment of stroke 70 and neural injury, 71 and we have also employed the multifactor restorative agent cerebrolysin for stroke therapy. 72, 73 All the pharmacological agents tested so far, which show evidence of being neurorestorative, induce brain plasticity, angiogenesis, neurogenesis and synaptogenesis. The molecular and signal transduction pathways by which these agents promote brain plasticity have also been investigated, and they appear to activate specific signaling pathways, such as PI3k/Akt 72,74-76 and sonic hedgehog (Shh). 77, 78 This article, however, is not a forum to discuss these pathways. We focus here on the observation that pharmacological agents by various means and multiple signal transduction pathways can induce CNS plasticity that enhances functional recovery from stroke and neural injury.
Cell-based Therapies for Stroke
The translation of these restorative agents from the laboratory to the clinic has to be performed with care and laboratory testing must be 81 Further studies demonstrated that the restorative effect to increasing NO could be attributed to the increase of cyclic guanosine monophosphate (cGMP), 60 a major signalling molecule. To confirm the role of cGMP as the target for the restorative therapeutic effect of NO, we sought another way to increase cGMP without increasing NO. cGMP can be increased in tissue by inhibiting its hydrolysis via PDE5. 63 Therefore, by using a PDE5 inhibitor, we would increase cGMP. 82 A widely used PDE5 inhibitor is sildenafil and we have tested sildenafil in preclinical stroke studies, demonstrating its efficacy in young and old animals, 83 with a therapeutic window of at least 30 days post-stroke. 84 Our studies have led to a Phase II clinical trial sponsored by Pfizer in which a PDE5 inhibitor is used as a restorative agent to treat stroke.
Cerebrolysin, a peptide-based drug, is a prime candidate for the treatment of stroke and neural injuries. 73 Multiple laboratories have demonstrated the safety and efficacy of this agent in the treatment of experimental stroke. 72, 85 Cerebrolysin is presently in clinical trials and is in common use in many countries for the clinical treatment of stroke. 86 We have demonstrated that cerebrolysin induces neurogenesis and angiogenesis in animal models of stroke and concomitantly enhances brain plasticity and recovery from stroke. 72 The full potential of this drug as a restorative agent for the treatment of stroke and neural injury awaits further investigation.
In this article, we have briefly described a novel approach to the treatment of stroke and neural injury, the use of agents to stimulate endogenous recovery mechanisms. Although neuroprotection remains a vital clinical target, it is our belief that therapeutic efficacy would be maximised with a focus on neurorestoration, the amplification of intrinsic CNS processes using cell-based or pharmacological based therapies. The therapeutic approach should be to minimise damage, via neuroprotective agents, and to maximise recovery through neurorestorative agents, treating the intact brain. n 
